NCT04531150

Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects

A Single Center, Phase I, Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Inversago Pharma Inc. · Industry
• Sex: All
• Age: 15 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Single center, randomized, double-blinded, placebo-controlled, single ascending-dose study for the evaluation of the safety, tolerability, and PK following single oral doses of INV-101.

Conditions

• Pharmacokinetic

Interventions

Type	Name	Description
DRUG	INV-101	Subjects will be randomized to receive INV-101 tablets
DRUG	Placebo	Subjects will be randomized to receive placebo tablets

Timeline

• Start date: 2020-09-08
• Primary completion: 2021-01-16
• Completion: 2021-05-16
• First posted: 2020-08-28
• Last updated: 2025-03-30

Locations

1 site across 1 country: Canada